It’s on again. Or so reports Bloomberg.
Bill Maris, who achieved rock star status in the venture world as the founder of Google Ventures, is once again just a step away from unveiling a new fund. But instead of the $230 million operation he had initially envisioned, Bloomberg quotes sources in the know saying that Maris is going to bankroll a $100 million fund, taking the lead role as sole investor.
Maris had a special fondness for biotech and healthcare when he helmed Alphabet’s powerful venture arm. His money — pumping along at a rate of a half billion dollars a year — came with the special hue of a Google endorsement, which undoubtedly helped the startups he backed. And he’s sticking with that early attraction to biotech.
First, though, he had to overcome some Hamlet-level doubts.
“(S)taring down the barrel of doing again exactly what I just did was not inspiring me, and I pulled the plug,” a reluctant Maris told Recode last December. “Life is too short to not be true to yourself. I’m still taking time off and exploring some other ideas that may be more fun and impactful.”
One of those other ideas apparently involved running a startup, according to Bloomberg’s breaking story.
Trekkies will cheer the name of this fund. Section 32 takes a cue from the security group (Section 31) on Star Trek. Once again, it’s time to head to unknown worlds, provided Maris can achieve liftoff this time.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription